Rainer Strohmenger

Rainer Strohmenger is a Managing Partner at Wellington Partners and one of Europe’s most experienced venture capitalists in Life Sciences. His more than 22 years of investment activity have involved financing of some of the most successful European biotech, medtech, diagnostics and healthcare IT companies. In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, which became the most successful venture-backed biopharmaceutical company in Europe and was acquired in 2017 by Johnson & Johnson for US$ 30 billion. He was also responsible for the investments in Definiens (acquired by Medimmune), Genkyotex (NYSE Euronext: GKTX), Grandis (acquired by Novartis), immatics (NASDAQ: IMTX), invendo medical (acquired by Ambu), mtm laboratories (acquired by Roche), NoemaLife (acquired by Dedalus), Oxford Immunotec (NASDAQ: OXFD) and Wavelight (acquired by Alcon). Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany. Rainer holds a M.D. in medicine as well as a M.Sc. in economics, both from Ludwig-Maximilians-University in Munich, Germany, and was trained at the Entrepreneurship Center of the MIT, Boston, USA. He is a Member of the VC Council at InvestEurope and a Member of the Senate at the German Association of Small and Medium-sized Businesses (BVMW).